PT-141

Overview

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH). It was originally developed from the melanocortin peptide Melanotan II. PT-141 is notable as a melanocortin receptor agonist with selectivity for MC3R and MC4R subtypes. While an FDA-approved pharmaceutical form exists (Vyleesi), the research-grade peptide remains widely used in preclinical melanocortin receptor studies.

Research Summary

PT-141 has been studied in both preclinical and clinical contexts as a melanocortin receptor agonist. Research has focused on MC3R and MC4R activation and downstream signaling through central nervous system pathways. Preclinical studies in animal models examined sexual behavior responses and melanocortin pathway activation. The peptide provides a research tool for studying melanocortin receptor pharmacology and central nervous system signaling. Research use focuses on receptor binding studies, neuroendocrine signaling, and melanocortin pathway characterization.

Proposed Mechanism of Action

PT-141 acts as an agonist at melanocortin receptors MC3R and MC4R in the central nervous system. Unlike PDE5 inhibitors, its mechanism involves hypothalamic signaling pathways rather than peripheral vascular effects. Research indicates it initiates signaling through the melanocortin system involving dopaminergic and oxytocinergic pathways.

Vendor Availability

Published Research References

References are provided for informational purposes. PeptiNox does not endorse or validate the conclusions of cited studies. All listed research pertains to preclinical or in vitro investigations unless otherwise noted.